Albendazole therapy for solitary persistent cysticercus granuloma.
Use of Albendazole therapy for the treatment of patients having persisting intracranial solitary cysticercus granuloma is controversial. Most of the times these patients are treated empirically with variety of drugs for variable period. Some authors advocate biopsy before definitive treatment. 25 patients having radiologicaly persistent solitary cysticercus granuloma (>6 months) were given 15 days course of oral albendazole (15 mg/kg body wt). Cranial CT scan was repeated one month after the completion of albendazole therapy. It was evaluated for complete resolution, partial response (> 50% decrease in size of lesion) or no change as compared to previous scan. 12 patients (48%) showed complete resolution, 4 patients (16%) showed a partial response, while 9 patients (36%) did not show any change on follow up. Albendazole therapy may be useful for patients having persistent cysticercus granuloma.
Thussu
A
A
Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160012, India.
Arora
A
A
Lal
V
V
Prabhakar
S
S
Sawhney
I M
IM
D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000008:administration & dosage*; D000871:Anthelmintics / Q000008:administration & dosage*; D002648:Child; D005260:Female; D006099:Granuloma / Q000188:drug therapy / Q000469:parasitology; D006801:Humans; D008297:Male; D008875:Middle Aged; D020019:Neurocysticercosis / Q000188:drug therapy*; D016896:Treatment Outcome
D000871:Anthelmintics; D015766:Albendazole